Regeneron and Sanofi Genzyme to Present Additional Data from Pivotal Phase 2b Dupilumab Study in Adults with Uncontrolled Persistent Asthma at the American Thoracic Society International Conference

You are now leaving Investor.Regeneron.com. The site you are about to visit is maintained by a third party who is solely responsible for its content. We encourage you to read the privacy policy of every website you visit.

Continue

Release Details

Regeneron and Sanofi Genzyme to Present Additional Data from Pivotal Phase 2b Dupilumab Study in Adults with Uncontrolled Persistent Asthma at the American Thoracic Society International Conference